Difference between revisions of "Apixaban (Eliquis)"

From HemOnc.org - A Hematology Oncology Wiki
Jump to navigation Jump to search
m (Text replacement - "please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [https://online.lexi.com/lco/action/login UpToDate Lexidrug], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the prescribing information" to "please refer to your preferred pharmacopeias or the prescribing information")
 
(25 intermediate revisions by 4 users not shown)
Line 1: Line 1:
−
'''FDA approved 12/28/2012'''. 
 
−
 
 
==General information==
 
==General information==
−
Class/mechanism: Selective and reversible factor Xa inhibitor. By inhibiting free and clotbound factor Xa in the coagulation cascade, apixaban inhibits prothrombinase activity, the conversion of prothrombin to thrombin, and the subsequent conversion of fibrinogen to fibrin. It does not need antithrombin III to exert its antithrombotic activity.<ref name="insert">[http://packageinserts.bms.com/pi/pi_eliquis.pdf Apixaban (Eliquis) package insert]</ref><ref>[[Media:Apixaban.pdf | Apixaban (Eliquis) package insert (locally hosted backup)]]</ref><ref>[http://www.eliquis.com Eliquis manufacturer's website]</ref>
+
Class/mechanism: Selective and reversible factor Xa inhibitor. By inhibiting free and clotbound factor Xa in the coagulation cascade, apixaban inhibits prothrombinase activity, the conversion of prothrombin to thrombin, and the subsequent conversion of fibrinogen to fibrin. It does not need antithrombin III to exert its antithrombotic activity.<ref name="insert">[https://packageinserts.bms.com/pi/pi_eliquis.pdf Apixaban (Eliquis) package insert]</ref><ref>[[:File:Apixaban.pdf | Apixaban (Eliquis) package insert (locally hosted backup)]]</ref><ref>[http://www.eliquis.com Eliquis manufacturer's website]</ref>
 
<br>Route: PO
 
<br>Route: PO
 
<br>Extravasation: n/a
 
<br>Extravasation: n/a
  
−
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [http://online.lexi.com/ Lexicomp], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the prescribing information.<ref name="insert"></ref>
+
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias or the prescribing information.<ref name="insert"></ref>
 +
 
 +
==Reversal information==
 +
[[Andexanet alfa (Andexxa)]] can bind, sequester, and reverse the anticoagulation effect of [[Rivaroxaban (Xarelto)|rivaroxaban]] and [[Apixaban (Eliquis)|apixaban]].
  
 
==Diseases for which it is used==
 
==Diseases for which it is used==
 
*Atrial fibrillation
 
*Atrial fibrillation
 +
*[[Venous thromboembolism]]
  
 
==Patient drug information==
 
==Patient drug information==
−
*[http://packageinserts.bms.com/pi/pi_eliquis.pdf#page=7 Apixaban (Eliquis) package insert pages 7-8]<ref name="insert"></ref>
+
*[https://packageinserts.bms.com/pi/pi_eliquis.pdf Apixaban (Eliquis) package insert]<ref name="insert"></ref>
 
*[http://www.uptodate.com/contents/apixaban-patient-drug-information Apixaban (Eliquis) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/apixaban-patient-drug-information Apixaban (Eliquis) patient drug information (UpToDate)]</ref>
 
*[http://www.uptodate.com/contents/apixaban-patient-drug-information Apixaban (Eliquis) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/apixaban-patient-drug-information Apixaban (Eliquis) patient drug information (UpToDate)]</ref>
  
 
==History of changes in FDA indication==
 
==History of changes in FDA indication==
−
*12/28/2012: FDA approves Apixaban (Eliquis) "to reduce the risk of stroke and dangerous blood clots (systemic embolism) in patients with atrial fibrillation that is not caused by a heart valve problem."<ref>[http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm333634.htm FDA approves Eliquis to reduce the risk of stroke, blood clots in patients with non-valvular atrial fibrillation (FDA.gov)]</ref>
+
*2012-12-28: Approved to reduce the risk of stroke and dangerous blood clots (systemic embolism) in patients with atrial fibrillation that is not caused by a heart valve problem.<ref>[http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm333634.htm FDA approves Eliquis to reduce the risk of stroke, blood clots in patients with non-valvular atrial fibrillation (FDA.gov)]</ref> ''(Non-hematologic indication)''
 +
*2014-03-13: Approved for the prophylaxis of [[Venous_thromboembolism|deep vein thrombosis (DVT), which may lead to pulmonary embolism (PE)]], in patients who have undergone hip or knee replacement surgery.
 +
*2014-08-21: Approved for the treatment of [[Venous_thromboembolism|DVT and PE]], and for the reduction in the risk of [[Venous_thromboembolism|recurrent DVT and PE]] following initial therapy.
 +
 
 +
==History of changes in EMA indication==
 +
*2011-05-18: Initial authorization
 +
==History of changes in PMDA indication==
 +
*2015-12-21: New additional indication and a new dosage for the treatment and prevention of the recurrence of [[venous thromboembolism]] (deep vein thrombosis and pulmonary thromboembolism).
 +
 
 +
==Also known as==
 +
*'''Brand name:''' Eliquis
  
 
==References==
 
==References==
 
<references/>
 
<references/>
  
−
[[Category:Drug index]]
+
[[Category:Drugs]]
−
[[Category:Hematology medications]]
+
[[Category:Oral medications]]
−
[[Category:Anticoagulants]]
+
[[Category:Direct oral anticoagulants]]
 
[[Category:Factor Xa inhibitors]]
 
[[Category:Factor Xa inhibitors]]
−
[[Category:Drugs FDA approved in 2012]]
+
 
 +
[[Category:Venous thromboembolism medications]]
 +
[[Category:EMA approved in 2011]]
 +
[[Category:FDA approved in 2012]]

Latest revision as of 01:06, 29 June 2024

General information

Class/mechanism: Selective and reversible factor Xa inhibitor. By inhibiting free and clotbound factor Xa in the coagulation cascade, apixaban inhibits prothrombinase activity, the conversion of prothrombin to thrombin, and the subsequent conversion of fibrinogen to fibrin. It does not need antithrombin III to exert its antithrombotic activity.[1][2][3]
Route: PO
Extravasation: n/a

For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias or the prescribing information.[1]

Reversal information

Andexanet alfa (Andexxa) can bind, sequester, and reverse the anticoagulation effect of rivaroxaban and apixaban.

Diseases for which it is used

Patient drug information

History of changes in FDA indication

  • 2012-12-28: Approved to reduce the risk of stroke and dangerous blood clots (systemic embolism) in patients with atrial fibrillation that is not caused by a heart valve problem.[5] (Non-hematologic indication)
  • 2014-03-13: Approved for the prophylaxis of deep vein thrombosis (DVT), which may lead to pulmonary embolism (PE), in patients who have undergone hip or knee replacement surgery.
  • 2014-08-21: Approved for the treatment of DVT and PE, and for the reduction in the risk of recurrent DVT and PE following initial therapy.

History of changes in EMA indication

  • 2011-05-18: Initial authorization

History of changes in PMDA indication

  • 2015-12-21: New additional indication and a new dosage for the treatment and prevention of the recurrence of venous thromboembolism (deep vein thrombosis and pulmonary thromboembolism).

Also known as

  • Brand name: Eliquis

References

  1. ↑ 1.0 1.1 1.2 Apixaban (Eliquis) package insert
  2. ↑ Apixaban (Eliquis) package insert (locally hosted backup)
  3. ↑ Eliquis manufacturer's website
  4. ↑ Apixaban (Eliquis) patient drug information (UpToDate)
  5. ↑ FDA approves Eliquis to reduce the risk of stroke, blood clots in patients with non-valvular atrial fibrillation (FDA.gov)
Retrieved from "https://hemonc.org/w/index.php?title=Apixaban_(Eliquis)&oldid=87396"